Since these agents are thesame chemicals as the thiazolidinedione (TZD) class of drugs that have beenused clinically for the treatment of diabetes (although recent concernsregarding side effects have limited their utility), it opens up the possibilitythat we may already have a means to manipulate CXCR4 levels in cancer. Here, CXCR4 is linked to cancer.